Relative Bioavailability Clinical Trial
Official title:
Relative Bioavailability of Tebipenem (SPR994) Crushed Tablet Formulation Administered by Nasogastric Tube in Healthy Subjects
The purpose of this study is to measure the amount of the antibiotic, tebipenem (SPR994) that is bioavailable after crushing the tablet and administering through a feeding tube with and without tube feeds.
This study will enroll 12 healthy volunteers and will take place in the Clinical Research Center at Hartford Hospital. Each volunteer will receive 2 doses (~22h washout period between doses) and will be randomly assigned to three treatment groups: 1) intact tebipenem 600mg dose (2 300mg tablets) taken orally; 2) a crushed tebipenem 600mg dose (2 300mg tablets) suspended in water and administered via the NGT; 3) a crushed tebipenem 600mg dose (2 300mg tablets) suspended in water and administered via a nasogastric tube with concurrent enteral tube feeds (run for 2h before dose and 4h post-dose). Crushed tablets will be administered by syringe through the nasogastric tube. An additional 150ml of water will be used to rinse out any remaining drug in syringe and administered to the volunteers to ensure delivery of the entire dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02052349 -
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01911741 -
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT03154840 -
Relative Bioavailability Among Different Eutropin Formulations
|
Phase 1 | |
| Completed |
NCT04814472 -
Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations
|
Phase 1 | |
| Completed |
NCT03934333 -
A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)
|
Phase 1 | |
| Not yet recruiting |
NCT06025344 -
A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
|
Phase 1 | |
| Not yet recruiting |
NCT06025318 -
An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers
|
Phase 1 | |
| Completed |
NCT04686669 -
A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations
|
Phase 1 | |
| Completed |
NCT03483259 -
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
|
Phase 1 |